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Increasing Tumor Volume Is Predictive of Poor Overall 
and Progression-Free Survival: Secondary Analysis of 
the Radiation Therapy Oncology Group 93-11 Phase I-II 
Radiation Dose-Escalation Study In Patients With 
Inoperable Non-Small-Cell Lung Cancer
Purpose
Patients with non–small-cell lung cancer (NSCLC) in the Radiation Therapy Oncology Group 
(RTOG) 93-11 trial received radiation doses of 70.9, 77.4, 83.8, or 90.3 Gy. The locoregional control 
and survival rates were similar among the various dose levels.We investigated the effect of the gross 
tumor volume (GTV) on the outcome.
Methods and Materials
The GTV was defined as the sum of the volumes of the primary tumor and involved lymph nodes. 
The tumor response, median survival time (MST), and progression-free survival (PFS) were analyzed 
separately for smaller (≤45 cm3) vs. larger (>45 cm3) tumors.
Results
The distribution of the GTV was as follows: ≤45 cm3 in 79 (49%) and >45 cm3 in 82 (51%) of 161 
patients. The median GTV was 47.3 cm3. N0 status and female gender were associated with better 
tumor responses. Patients with smaller (≤45 cm3) tumors achieved a longer MST and better PFS 
than did patients with larger (>45 cm3) tumors (29.7 vs. 13.3 months, p < 0.0001; and 15.8 vs. 8.3 
months, p < 0.0001, respectively). Increasing the radiation dose had no effect on the MST or PFS. 
On multivariate analysis, only a smaller GTV was a significant prognostic factor for improved MST 
and PFS (hazard ratio [HR], 2.12, p = 0.0002; and HR, 2.0, p = 0.0002, respectively). The GTV as a 
continuous variable was also significantly associated with the MST and PFS (HR, 1.59, p < 0.0001; 
and HR, 1.39, p < 0.0001, respectively).
Conclusions
Radiation dose escalation up to 90.3 Gy did not result in improved MST or PFS. The tumor responses 
were greater in node-negative patients and women. An increasing GTV was strongly associated 
with decreased MST and PFS. Future radiotherapy trials patients might need to use stratification by 
tumor volume. ©2008 Elsevier Inc.
Key Words: Tumor volume, Lung cancer, Radiotherapy dose escalation.
Introduction 
The current American Joint Committee on Cancer staging system for the primary tumor in lung 
cancer is based mostly on the tumor extent and involvement of the neighboring structures (e.g., 
pleura, chest wall, mediastinum, bone, esophagus, and proximal airways) rather than on tumor 
size or volume. A notable exception is Stage T1, in which a tumor surrounded completely by lung 
parenchyma cannot exceed 3 cm in the largest dimension. However, a Stage T2 tumor can measure 
1.5 cm or 8 cm, as long as it invades the visceral pleura only, with sparing of the other structures. 
Evidence has been accumulating1–11 that an 
increasing tumor volume has a significant 
effect on patient outcome, possibly even 
overriding the T stage assignment. Other factors 
influencing the American Joint Committee on 
Cancer stage assignment are nodal involvement 
and the presence of distant metastases.
In a recently published Radiation Therapy 
Oncology Group (RTOG) Phase I-II study12 
of radiation dose escalation for patients 
with inoperable non–small cell-lung cancer 
(NSCLC), the observed locoregional control 
rates and survival rates were similar between 
treatment groups, receiving escalated radiation 
doses (from 70.9 Gy to 90.3 Gy, depending on 
the volume of lung receiving ≥20 Gy [V20]).
A reasonable initial hypothesis would be, 
however, to expect that smaller tumors should 
demonstrate improved local control with greater 
radiation doses compared with larger tumors.
To investigate this hypothesis, we undertook a 
retrospective analysis of data from the RTOG 
93-11 clinical trial in an attempt to demonstrate 
any benefit of radiation dose escalation for 
patients with smaller tumors and to determine 
any relationship between the initial tumor 
volume and patient outcome.
Methods And Materials
Patient population
The RTOG 93-11 study was a Phase I-II 
radiation dose escalation trial for patients with 
inoperable Stage I-III NSCLC treated with 
three-dimensional (3D) radiotherapy alone, 
without concurrent chemotherapy, although 
induction chemotherapy was allowed. 
The primary objective of the study was to 
determine the treatment-related morbidity and 
to determine the maximal tolerated radiation 
dose. The secondary objectives were to 
determine the local control and overall survival 
(OS) rates. The patient population consisted of 
subjects with NSCLC (inoperable Stage I, II, 
and IIIA and Stage IIIB; supraclavicular nodes 
involvement was not allowed; Table 1). Patients 
were treated according to the volumetric 
treatment planning computed tomography 
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findings and the gross tumor volume (GTV) included the primary 
tumor and any enlarged regional lymph nodes (>1 cm) with a minimal 
3D margin of 1 cm. Noninvolved nodal areas were not irradiated, and 
no special effort was made to account for the respiratory motion, apart 
for assessing motion with fluoroscopy. Patients were placed into dose-
escalation groups according to the V20 value in their radiotherapy (RT) 
plan, predicting the likelihood of treatment-related pneumonitis13. 
Patients with a V20 of <25% were assigned to Group 1 and received 
an escalated dose to 70.9, 77.4, 83.8, or 90.3 Gy. Patients with a V20 of 
26–35% were assigned to Group 2 and received an escalated dose to 70.9, 
77.4, or 83.8 Gy. Patients with a V20 of >35% were assigned to Group 3 
and received an escalating dose to 64.5, 70.9, or 77.4 Gy. All fraction sizes 
were 2.15 Gy. The study accrued patients only to Groups 1 and 2. Group 
3 enrollment was stopped because of poor accrual.
Evaluation of local control, OS, and progression-free survival
A chest X-ray was obtained 4 weeks after RT completion. Computed 
tomography scans of the chest were obtained at 6 and 12 months and 
repeated yearly thereafter. Local control (complete response [CR] or 
partial response [PR] vs. stable or progressive disease) was reported by 
the enrolling institutions. No central review of the follow-up computed 
tomography scans was performed. OS and progression-free survival 
(PFS) were reported as measured from the date of registration in
the study.
Statistical analysis
The GTV was defined as the sum of the volumes of the primary tumor 
and involved lymph nodes. In the 3D plans, the primary tumor volume 
and the involved nodal volume were outlined as one structure; no data 
are available in the RTOG electronic database to allow for separation of 
those two volumes. Therefore, in an attempt to at least partially correct 
this deficiency, nodal status (N0 vs. N1 or N2 or N3) was analyzed as 
one of the variables. This allowed for the separation of the effect of 
the tumor GTV vs. nodal GTV (at least for Stage I, or N0, patients). 
OS was defined as death from any cause; an event for PFS was local or 
regional progression, distant metastases, or death from any cause. For 
the purpose of this investigation, tumor response, OS, and PFS were 
analyzed separately for the smaller tumors (≤45 cm3) vs. larger tumors 
(>45 cm3), first among all patients and, later, within each radiation dose 
level. GTV was also analyzed as a continuous variable. The association 
of response (CR/PR vs. stable/progressive disease) and the GTV 
categorized by cutpoint was tested by Fisher’s exact test. OS and PFS were 
estimated by the Kaplan-Meier method and tested using the log–rank 
test statistic. Univariate and multivariate analyses of OS and PFS with the 
GTV and other prognostic factors (age [<60 vs. ≥60], gender, Karnofsky 
performance status [90–100 vs. 70–80], histologic type [nonsquamous 
vs. squamous], stage [I-II vs. IIIA-IIIB], previous chemotherapy [yes vs. 
no], and maximal radiation dose to the lung) were done using the Cox 
proportional hazards model. Multivariate modeling used the stepwise 
selection method. When analyzed as a continuous variable, GTV was 
transformed using a log10 transformation to ensure normality. Patients 
with unknown tumor volumes were excluded from this analysis.
Results
Patient characteristics
A total of 176 patients were included in the original report of the study12. 
Of the 176 patients, 161 had available data on GTV and tumor response 
and were the subject of this secondary analysis. The patient characteristics 
are presented in Table 1. Overall, most patients were older (>60 years) 
with a Karnofsky performance status between 70 and 80. The patients in 
this analysis were approximately equally split between men and women 
and those in Group 1 were more likely to have node-negative disease 
than were those in Group 2. The distribution of the American Joint 
Committee on Cancer stage was Stage I in 67, Stage II in 12, and Stage 
III in 48 patients in Group 1 and Stage I in 10, Stage II in 3, and Stage III 
in 35 patients in Group 2.
Tumor response, OS, and PFS
The GTV was ≤45 cm3 in 79 (49%) and >45 cm3, 82 (51%) of 161 patients 
(median, 47.3; range, 1.9–1,039.9 cm3); 14 patients had an unknown 
GTV. The tumor response rate (CR/PR) was better for smaller tumors 
(≤45 cm3) than for larger tumors (>45 cm3; 87% vs. 76%, respectively), 
as was stable/progressive disease (13% vs. 24%, respectively; p = 
0.0691, Fisher’s exact test). Results using a cutoff point of 30 cm3 did 
not better distinguish between those patients with a tumor response 
and those with stable or progressive disease than using a cutoff point 
of 45 cm3 (p = 0.0642). A cutoff point of 60 cm3 did not discriminate 
between the two groups (p = 0.4139). When the GTV was analyzed as a 
continuous variable, on univariate analysis, it was borderline statistically 
significantly associated with tumor response (p = 0.0551); however, on 
multivariate analysis, N stage (N0 vs. N1-N3) and female gender were 
the only significant variables (p = 0.025 and p = 0.02, respectively). This 
can be explained by the greater rate of responses (70%) in patients with 
N0 disease vs. N1-N3 (30%).
Patients with smaller tumors (≤45 cm3) achieved a longer median survival 
than did patients with larger tumors (>45 cm3; 29.7 vs. 13.3 months, p 
< 0.0001; Fig. 1), as well as better median PFS (15.8 vs. 8.3 months; p < 
0.0001; Fig. 2).
When a different GTV was chosen as a cutoff point (30 cm3 or 60 cm3), 
patients with smaller tumors (≤30 cm3 or ≤60 cm3) still achieved better 
OS (32.9 vs. 14.6 months for 30 cm3, p = 0.0002; and 26.8 vs. 13.3 months 
for 60 cm3, p = 0.0006), as well as better PFS (15.5 vs. 9.0 months for 30 
cm3, p = 0.0031; and 14.7 vs. 8.7 months for 60 cm3, p = 0.0023).
Table 1. Patient characteristics
Characteristic  Group 1 (n = 127)  Group 2 (n = 48)
Age (y)
  <60   18 (14)   5 (10)
 ≥60 109 (86)  43 (90)
Gender (n)
 Male  72 (57)  22 (46)
 Female  55 (43)  26 (54)
KPS (n) 
 70–80  85 (67)  30 (63)
 90–100  42 (28)  18 (37)
Histologic type (n)
 Squamous cell carcinoma 51 (40)  21 (44)
 Adenocarcinoma  42 (33)  17 (35)
 Other  34 (21)  10 (21)
N stage (n)
 N0  83 (65)  17 (35)
 N1  10 (8)    6 (13)
 N2  32 (25)  22 (46)
 N3    2 (1)    3 (6)
Abbreviation: KPS = Karnofsky performance status.
Data in parentheses are percentages.
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When the effect of GTV was analyzed on univariate analysis, a smaller 
GTV was associated with improved OS, with significant hazard ratios 
(HRs) for cutoff points of 30 cm3 (HR, 2.15; p = 0.0002); 45 cm3 (HR, 
2.14; p < 0.0001); and 60 cm3 (HR, 1.91; p = 0.0008), as well as for GTV 
analyzed as a continuous variable (HR, 1.59; p < 0.0001). The other 
variables associated with improved OS on univariate analysis were female 
gender (p = 0.0407) and nodal status (p = 0.067, borderline significance). 
The same factors were significant for PFS on univariate analysis (data 
not shown).
On multivariate analysis of the factors associated with improved OS 
and PFS, only a smaller tumor volume was significantly prognostic 
for both endpoints (HR, 2.12; p = 0.0002; and HR, 2.0; p = 0.0002, 
respectively) when GTV was analyzed as a continuous variable. Age, 
gender, performance status, histologic type, N stage (N0 vs. N1-N3), 
previous chemotherapy, and maximal radiation dose were not significant 
(Tables 2 and 3). The other GTV cutoff points (≤30 cm3, ≤45 cm3, and ≤60 
cm3) retained their statistically significant association with improved OS 
and PFS on multivariate analysis and again were the only factors in the 
multivariate models using a stepwise selection method.
Effect of radiation dose escalation on tumor response, OS, and PFS by 
tumor volume
The primary research hypothesis of this study was that higher radiation 
doses would lead to increased efficacy in smaller tumors. Table 4 shows 
the frequencies and percentages of patients with a CR/PR and stable or 
progressive disease for each radiation dose and GTV combination using 
the 45 cm3 cutoff point. No evidence was found in these data that the CR/
PR rates increased as the radiation dose increases for the two categories 
of GTV (p = 0.2213). Increasing the radiation dose had no effect on OS 
or PFS (data not shown for PFS) when examined separately for smaller 
vs. larger tumors when the 45-cm3 GTV cutoff point was used (Table 
5). The results for the 30-cm3 and 60-cm3 cutoff points were similar 
(data not shown). The consistently statistically significant increase in the 
relative risk of death for all doses to a GTV >45 cm3 can be attributed to 
the strong effect of a larger GTV on OS rather than the radiation dose. 
However, the analysis was not powered to detect a dose–tumor volume 
interaction, and it could not be ruled out on the basis of this analysis.
Discussion
The aim of RTOG 93-11 was to determine the dose-limiting toxicity of 
3D RT. The radiation dose was safely escalated to 83.8 Gy for patients 
with V20 <25% and to 77.4 Gy for patients with a V20 of 25–36%. The 
90.3-Gy dose level was too toxic. The observed locoregional control was 
similar among the study arms, without evidence that the higher doses 
eliminated or at least lowered the recurrence rates.
Our initial hypothesis was that patients with volumetrically smaller 
tumors would have improved survival with radiation dose escalation but 
not patients with larger tumors. However, we were not able to demonstrate 
that in this secondary analysis of the RTOG 93-11 trial, at least not with 
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Figure 1. Five-year overall survival rate for patients with gross tumor 
volume ≤45 cm3 (solid curve) vs. those with gross tumor volume >45 
cm3 (dotted curve).
Figure 2. Five-year progression-free survival rate for patients with gross 
tumor volume ≤45 cm3 (solid curve) vs. those with gross tumor volume 
>45 cm3 (dotted curve).
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Table 2. Multivariate analysis of overall survival for 
different gross tumor volumes used as cutoff point and 
as continuous variable
 Model* Comparison  Hazard ratio  95% CI  p†
GTV (cm3)  <30 vs. ≥30  2.18  1.43–3.32  0.0003
GTV (cm3)  ≤45 vs. >45  2.12  1.43–3.13  0.0002
GTV (cm3)  ≤60 vs. >60  1.87  1.27–2.75  0.0015
GTV‡  Continuous  1.59  1.33–1.91  <0.0001
Abbreviation: CI = confidence interval; GTV = gross tumor volume; KPS = Karnofsky performance status.
*Following covariates did not meet entry criteria for any multivariate model: age (<60 vs. ≥60 y), gender 
(female vs. male), KPS (90–100 vs. 70–80), histologic type (nonsquamous vs. squamous), N stage (N0 vs. 
N1-N3), previous chemotherapy (no vs. yes), or maximal dose to lung (continuous).
†Chi-square test using Cox proportional hazards model; stepwise selection, with entry level of 0.05 and exit 
level of 0.10.
‡GTV transformed using log10 to ensure normalcy.
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the small patient numbers that were available at each radiation dose 
level tested. It could be that doses >83.8 Gy in standard fractions are 
necessary to eliminate local failure. Additionally, the protracted overall 
treatment time of 7–9 weeks might have facilitated tumor repopulation 
and therefore attenuated any radiation dose response. Finally, the 
PTV margins were tight (1–1.5 cm around the GTV), which might 
have increased the likelihood for a marginal miss in mobile tumors, 
obliterating any potential benefit of dose escalation.
Such a benefit has been suggested in the Memorial Sloan-Kettering 
Cancer Center experience4, with the observation of improved local 
control and survival in Stage III NSCLC patients with large (>100 cm3) 
tumors treated with radiation doses >64 Gy compared with those who 
received lower radiation doses.
A significant interaction between radiation dose and tumor size was 
shown in the University of Michigan retrospective analysis5 of 114 
patients with medically inoperable Stage I and II NSCLC treated with 3D 
conformal RT in a dose-escalation study. Patients treated to a biologically 
equivalent dose of ≤79.2 Gy lived longer if their tumors did not exceed 
51.8 cm3 in volume. However, patients treated to a biologically equivalent 
dose of >79.2 Gy had the same overall survival, irrespective of tumor 
volume. With all the limitations of the retrospective study, a hypothesis 
has been raised that radiation dose escalation can result in improved 
outcome in NSCLC, at least in node-negative, early-stage tumors.
In the reports of highly hypofractionated (‘‘radioablative’’) RT using 
precise localization techniques to account for tumor motion, very high 
local control rates have been achieved in medically inoperable patients 
with Stage I NSCLC receiving 60 Gy in three fractions of 20 Gy each10 
or other hypofractionated regimens11. Such doses have not yet been 
tested in Stage III NSCLC and might be too dangerous for large and
central tumors.
We found that the increasing tumor volume, defined as the sum of the 
primary tumor volume and the volume of the involved lymph nodes, 
was associated with a greater risk of local failure, with significantly better 
control achieved with tumors <45 cm3 than with the larger tumors. The 
45-cm3 volume corresponds roughly to a spherical tumor diameter of
4.4 cm. It must be remembered that the ‘‘tumor volume’’ in our analysis 
denoted a sum of the volume of the primary tumor and the involved 
lymph nodes, if any. However, in the multivariate analysis of the tumor 
volume studied as a continuous variable, it was only the earlier nodal 
stage and female gender, not the tumor volume, that was associated with 
better local control. In reality, those two variables (volume and nodal 
stage) overlap to a large degree, because Stage I NSCLC is defined as a 
node-negative tumor measuring ≤3 cm in the largest dimension. Separate 
values for the primary GTV and the nodal GTV were not available in the 
RTOG 93-11 study; therefore, we were unable to isolate their respective 
influences on outcomes.
Because a rigorous evaluation of locoregional control was not performed 
in the RTOG 93-11 trial, local control was not assessed in an actuarial 
fashion and the radiographic responses might not reflect the true biologic 
tumor elimination; using survival as an endpoint is a more objective 
measure of the relevance of tumor volume. A strong association of 
increasing tumor volume with worsened survival and PFS was observed 
in our analysis, overriding other known prognostic factors for survival, 
such as lower disease stage.
Such an association has been previously reported1–9. In 207 patients with 
inoperable NSCLC (Stage I-III) treated at the Washington University 
with 3D-conformal thoracic RT1, overall survival, cause-specific 
survival, and local tumor control were highly correlated with the GTV, 
and the GTV (and pathologic findings) were predictive for survival on 
multivariate analysis, but overall stage and nodal stage were not. Those 
patients with tumor volumes not exceeding 33 cm3 appeared to have the 
best outcome.
Local response was evaluated volumetrically on 107 followup thoracic 
computed tomography scans of 22 patients (19 with Stage III NSCLC) 
Table 3. Multivariate analysis of progression-free survival for 
different gross tumor volumes used as cutoff point and as
continuous variable
 Model* Comparison  Hazard ratio  95% CI  p†
GTV (cm3)  <30 vs. ≥30  1.74  1.20–2.53  0.0039
GTV (cm3)  ≤45 vs. >45  2.00  1.40–2.86  0.0002
GTV (cm3)  ≤60 vs. >60  1.65  1.16–2.36  0.0056
GTV‡  Continuous  1.39  1.18–1.64  <0.0001
Abbreviations as in Table 2.
*Following covariates did not meet entry criteria for any multivariate model: age (<60 vs. ≥60 y), gender 
(female vs. male), KPS (90–100 vs. 70–80), histologic type (nonsquamous vs. squamous), N stage (N0 vs. 
N1-N3), previous chemotherapy (no vs. yes), or maximal dose to lung (continuous).
†Chi-square test using Cox proportional hazards model; stepwise selection, with entry level of 0.05 and exit 
level of 0.10.
‡GTV was transformed using log10 to ensure normality.
Table 4. Frequency of tumor response subdivided by radiation
dose level and gross tumor volume cutpoint of 45 cm3
Incidence (n)
GTV ≤45 cm3  CR/PR  SD/PD  p*
Dose 70.9 Gy  13 (93) 1 (7)  0.2736
Dose 77.4 Gy  14 (82) 3 (18)
Dose 83.8 Gy  15 (88)  2 (12)
Dose 90.3 Gy  23 (88)  3 (12)
Dose 70.9 Gy  21 (70)  9 (3)
Dose 77.4 Gy  19 (68)  9 (32)
Dose 83.8 Gy  12 (92)  1 (8)
Dose 90.3 Gy  8 (89)  1 (11)
Abbreviation: CR = complete response; PR = partial response; SD = stable disease; PD = progressive disease; 
GTV = gross tumor volume.
Data in parentheses are percentages. 
*Fisher’s exact test.
Table 5. Multivariate analysis of overall survival subdivided by 
radiation dose level and gross tumor volume cutpoint of 45 cm3
 Model* n  Hazard ratio  95% CI  p†
GTV ≤45 cm3, dose 83.8 Gy  17  1.60  0.65–3.93  0.3058
GTV ≤45 cm3, dose 77.4 Gy  17  1.10  0.43–2.82  0.8432
GTV ≤45 cm3, dose 70.9 Gy  14  1.57  0.63–3.91  0.3301
GTV >45 cm3, dose 90.3 Gy  9  4.20  1.52–11.64 0.0058
GTV >45 cm3, dose 83.8 Gy  13  3.83  1.53–9.60  0.0041
GTV >45 cm3, dose 77.4 Gy  28  2.41  1.06–5.48  0.0361
GTV >45 cm3, dose 70.9 Gy  30  2.61  1.17–5.84  0.0193
Abbreviations as in Table 4.
Reference level: GTV ≤45 cm3, dose 90.3 Gy.
*Chi-square test using Cox proportional hazards model.
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treated with definitive thoracic RT2. A volumeof ≤63cm3 and a diameter of 
≤4 cm were significantly associated with improved local control compared 
with larger volumes or diameters. In a large series from Wuerzburg6, 784 
scans of 136 patients were evaluated volumetrically, and a cutoffpoint of 
100 cm3 for tumor volume was a discriminating factor for local control, 
but not survival. In that study, the primary tumor volume and nodal 
volume were measured separately. The total tumor volume (tumor 
plus nodes), as well as primary tumor volume alone, was a significant 
prognostic factor for survival in a Japanese group experience7.
Because most of the studies cited in our report included a significant 
proportion of patients with nodal involvement (N1-N3), the relative 
prognostic value of the ‘‘T’’ tumor volume vs. the ‘‘N’’ nodal volume 
needs to be elucidated. One would expect that worse survival and possibly 
lower local control would be associated with an increasing nodal volume 
rather than the primary tumor volume. However, contradictory data 
have been published on this issue. On univariate analysis of the factors 
associated with overall survival and failure-free survival in a Phase I-
II radiation dose-escalation trial3, only the increasing GTV (defined as 
tumor plus nodes), but not the nodal stage or the overall stage, were 
predictive. Similarly, in the Japanese experience7 of 71 patients with 
Stage III NSCLC, on univariate analysis, the total tumor volume and the 
primary tumor volume were significant and the nodal volume was not. 
On multivariate analysis, the total tumor volume and primary tumor 
volume were both significant prognostic factors.
Investigators from Shanghai Medical University8 created a prognostic 
index model predicting for local control in patients with NSCLC treated 
with RT. Patients with a smaller tumor volume (primary plus nodal), 
earlier clinical stage, and treated with higher total irradiation dose with 
a shortened overall treatment time had better local control.
In a Classification and Regression Tree analysis of the Thomas Jefferson 
University’s 107 patients with Stage III NSCLC (9), an aggregate nodal 
volume >12.5 cm3 (sum of volumes of the abnormal hilar and mediastinal 
lymph nodes), as well as a central tumor location, but not the primary 
tumor volume, were associated with a greater risk of nodal recurrence 
and shorter median survival time than a nodal volume of ≤12.5 cm3 
(MST 13.9 months vs. 17.1 months, respectively). We are not aware of 
other reports that have focused on the prognostic value of the involved 
nodal volume.
Conclusions
Our study is one of several publications demonstrating the importance 
of tumor volume in patients receiving thoracic RT for NSCLC. It is not 
fully clear whether patients with smaller tumors have better outcomes 
simply because of the lower number of clonogenic cells or whether 
smaller tumors are inherently more biologically favorable; however, the 
tumor volume may need to be considered in the staging system for lung 
cancer, once user-friendly volume assessment becomes commonplace in 
diagnostic studies.
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